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Introduction
Atrial fibrillation (AF) is the most common chronic cardiac 
arrhythmia (1, 2). Major mortality and morbidity are associated with 
stroke and systemic embolism in patients with AF (3). The CHA2DS2-
VASc is a clinical score for estimating the risk of stroke in patients 
with non-valvular AF and is used to determine whether anticoagula-
tion therapy treatment is required or not (2-4). The numerous limita-
tions of the clinical usage of warfarin have led clinicians to search for 
alternative agents. New oral anticoagulants (NOACs), such as dabiga-
tran, appear to be preferable in these patients (5, 6). Herein, we pres-
ent a patient with acute ischemic stroke (AIS) occurring under dabi-
gatran treatment, causing fainting, which resulted in a traumatic large 
lower leg hematoma.
Case Report
An 82-year-old lethargic female patient was admitted to our emer-
gency department with complaint of sudden loss of consciousness. On 
physical examination, a traumatic large hematoma (21x16 cm) was 
noticed on her right lower leg. On neurological examination, motor 
aphasia and right hemiplegia were observed. Ten months ago, she had 
been diagnosed with a transient ischemic attack, persistent AF, and 
hypertension. Based on the European Society of Cardiology (ESC) 
Committee Guidelines (2), she had been considered to be in a high-risk 
group (CHA2DS2-VASc score: 6 points), and 110 mg oral dabigatran 
(b.i.d.) had been initiated as an anticoagulant. Brain computerized 
tomography showed hypoattenuation in the left frontoparietal subcor-
tical deep white matter and sulcal effacement in the left frontal lobe, 
Figure 1. A, B. Axial NECT (non-enhanced computerized tomography) 
images show hypoattenuation and sulcal effacement in the left middle 
cerebral artery distribution (arrows)
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Figure 2. A photograph of the large hematoma after linear incision for 
drainage
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which are compatible with acute middle cerebral artery infarction 
(Fig. 1). Her creatinine clearance was within normal limits. Her acti-
vated partial thromboplastin time (aPTT) and international normalized 
ratio (INR) levels were 61.7 sec and 1.3, respectively. On follow-up, 
she became stable gradually and regained consciousness within 2-3 
hours. Dabigatran was stopped. A linear incision was made to drain 
the large hematoma on her right lower leg (Fig. 2). Homeostasis was 
ensured 36 hours after administration, and subcutaneous enoxapa-
rin was initiated. The patient was referred to another hospital for 
reconstruction surgery. At that facility, a diagnosis of ischemic 
stroke was confirmed by cerebral magnetic resonance imaging 
(MRI) and diffusion MRI. After a successful operation, dabigatran 
150 mg (b.i.d.) was initiated on the 15th day, and since then she has 
had no complaints.
Discussion
Unlike warfarin, dabigatran has a predictable pharmacokinetic 
profile with minimal adverse interactions and allows a fixed-dose regi-
men, so that monitorization of its activity by standard blood tests is not 
required. Although there is no specific antidote in the case of major 
bleeding, discontinuation of dabigatran is generally sufficient to reverse 
its activity because of its short half-life (6). General clinical recommen-
dations on this NOAC are well defined. Nevertheless, a lack of long-
term follow-ups and real world experience is its main handicap (5). 
Thrombin clotting time (TT) and aPTT are accessible qualitative meth-
ods for determining the anticoagulant effects of dabigatran; however, 
they have low sensitivity at supratherapeutic levels (6, 7). Due to the 
lack of a facility, TT could not be measured in our patient, and despite 
mildly elevated aPTT levels, a serious extracranial hemorrhagic compli-
cation occurred.
Concomitance of these two different complications (hemorrhagic 
and ischemic), the managements of which are completely different, 
makes our case more complicated and significant. Clinical trials have 
shown that dabigatran (110 mg b.i.d.), rivaroxaban, and apixaban pro-
vide similar protection from AIS in AF patients compared to well-
controlled warfarin (7-9). Only dabigatran (150 mg b.id.) showed 
superiority in this efficacy endpoint (7). The 2012 ESC guidelines sug-
gest that clinicians may consider the use of dabigatran 150 mg b.i.d. in 
patients with AIS occurring while taking an NOAC (2). However, clini-
cians should assess patients’ bleeding risks before increasing the 
dosage of dabigatran. Because there are no clinical research data 
available about AIS under 150-mg dabigatran treatments, physicians 
may choose different treatment pathways that they tailor for each 
patient’s needs. Switching the treatment with warfarin or another 
NOAC, like rivoraxaban or apixaban, the action mechanisms of which 
are different, or continuing to use 150 mg dabigatran (b.i.d.) are pos-
sible treatment options. Combination of an NOAC with an antiplatelet 
agent is another alternative. However, it was shown that combination 
therapy increases the bleeding risk but does not change the AIS rate 
(6, 10).
In our case, although the dosage of dabigatran needed to be 
increased to 150 mg, it was stopped initially due to the presence of a 
large hematoma. This dilemma is not rare, and current guidelines are 
insufficient. There is no certainty about which anticoagulant should be 
preferred in these cases. Despite having a short half-life and low risk of 
hemorrhage, NOACs are not generally preferred in the acute manage-
ment of such cases due to lack of experiences.
Conclusion
Despite the rapidly increasing the usage of NOACs, the lack of stan-
dard monitorization or specific antidote in emergency situations, as 
well as many reports about their hemorrhagic side effects, indicates 
that the clinicians should not be comfortable while using these drugs, 
especially in high-risk patients. The management of some certain clini-
cal situations, such as serious hemorrhagic and ischemic complica-
tions in patients who are on NOAC, and the optimal timing of the initia-
tion of NOACs following AIS are still controversial.
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